objective: allogeneic transplantation with umbilical cord blood (ucb) in adult recipients is limited mainly by a low cd34+ cell dose. to overcome this shortcoming, human placenta as a novel source of human mesenchymal progenitor cell (mpc)- unrestricted somatic stem cells (ussc)- was incorporated in an attempt to expand cd34+ cells from ucb. to provide a similar environment in vitro, we coated ...

The use of hematopoietic cell transplantation has expanded and evolved substantially in the last decade. New stem cell sources and stem cell mobilizing agents have been introduced in clinical practice. The incidence of life-threatening complications following autologous stem cell transplant procedures has decreased dramatically. Understanding the immune mediated effect of allogeneic stem cell t...

Hematopoietic stem-cell transplantation (HSCT) refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrowtoxic doses of cytotoxic drugs, with or without whole body radiation therapy. Stem cells may be obtained from the transplant recipient (autologous HSCT) or can be harvested from a donor (allogeneic HSCT). Ste...

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for a variety of malignant and non-malignant hematological and congenital diseases. Due to the fact that the human leukocyte antigen system is inherited independently of the blood group system, approximately 40-50% of all HSCTs are performed across the ABO blood group barrier. The expected immune-hematological conseq...

plantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor. Blood 1995; 85:1666-72. 5. Elmaagacli AH, Beelen DW, Becks HW, et al. Molecular studies of chimerism and minimal residual disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation. Bone Marrow Transplant 1996; 18:397-403. 6. Schwartzberg L, Bi...

The occurrence of graft rejection and/or graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is largely depended on whether the re‐ cipient and the donor have matched HLA types. Under normal circumstances, the individu‐ al with completely matched HLA antigens can be the donor. However, due to the high level of HLA polymorphism, the major obstacl...

BACKGROUND Hematopoietic stem cell transplantation (HSCT) has been considered as an effective approach at inducing allogeneic hematopoietic reconstitution and immune tolerance. However, it remains critical to find the optimal HSCT delivery method and robust sources of hematopoietic stem cells (HSCs). MATERIAL AND METHODS We introduced a new method by infusing allogeneic endosteal bone marrow ...

The first hematopoietic stem cell transplantation (HSCT), the replacement of the hematopoietic system, by hematopoietic stem cells from the patient (autologous HSCT) or from another person (allogeneic HSCT), was performed almost 45 years ago. Today autologous HSCT is used to bridge hematopoietic failure after high dose chemotherapy for the treatment of selected hematopoietic and non-hematopoiet...